Advertisement


Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

David A. Hyman, MD, JD, on Inclusive Shared Savings

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Advertisement